# TNGX catalysts: Tango Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tngx/catalysts

> Tango Therapeutics, Inc. (TNGX) has 2 upcoming catalysts. The next is the glioblastoma interim data readout, Jan 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Tango Therapeutics, Inc. |
| Ticker | TNGX (Nasdaq) |
| SEC CIK | 1819133 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tngx |

## Cash runway

Cash $977.5M as of 2026-09-30; quarterly burn $37.1M; about 79.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-452634).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 10, 2022 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000095017025028345/tngx-ex99_1.htm)) |
| Jul 2023 | [Vopimetostat trial start](https://sec-api.dev/pdufa/vopimetostat) | TNGX |  | completed | "The first patient was dosed in July 2023 and we are currently enrolling patients at 250 mg QD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm)) |
| Q2 2025 | [Glioblastoma trial start](https://sec-api.dev/pdufa/glioblastoma) | TNGX | MTAP-deleted solid tumors, focused | scheduled | "The Company plans to begin enrolling a Phase 1/2 clinical trial evaluating TNG456 in patients with MTAP-deleted solid tumors, focused on glioblastoma in 2Q 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/tngx-ex99_1.htm)) |
| May 12, 2025 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/tngx-ex99_1.htm)) |
| August 5, 2025 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/tngx-ex99_1.htm)) |
| November 4, 2025 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312525263684/tngx-ex99_1.htm)) |
| March 5, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/tngx-ex99_1.htm)) |
| May 13, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/tngx-ex99_1.htm)) |
| Jun 2026 | [Vopimetostat trial start](https://sec-api.dev/pdufa/vopimetostat) | TNGX |  | scheduled | "In June 2026, we announced our plans to initiate a Phase 3 clinical trial of vopimetostat in combination with daraxonrasib in front-line pancreatic cancer." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526266074/d151329d424b5.htm)) |
| June 8, 2026 | [Vopimetostat interim data readout](https://sec-api.dev/pdufa/vopimetostat) | TNGX |  | completed, positive | "BOSTON, June 8, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive initial data from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination with Revolution Medicines' RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/d158334dex991.htm)) |
| 2H 2026 | [Glioblastoma interim data readout](https://sec-api.dev/pdufa/glioblastoma) | TNGX |  | scheduled | "We anticipate providing initial clinical data from this trial in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819133/000119312526343424/tngx-20260630.htm)) |
| August 11, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/tngx-ex99_1.htm)) |
| November 9, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526452635/tngx-ex99_1.htm)) |
| Jan 2027 | [Glioblastoma interim data readout](https://sec-api.dev/pdufa/glioblastoma) | TNGX |  | scheduled | "We anticipate providing initial clinical data from this trial in January 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819133/000119312526452634/tngx-20260930.htm)) |
| 1H 2027 | [Vopimetostat trial start](https://sec-api.dev/pdufa/vopimetostat) | TNGX | MTAP-wild type pancreatic cancer | scheduled | ""Following discussions with the U.S. FDA, we are focused on initiating a planned registrational Phase 3 trial of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613dex991.htm)) |

## Drugs

- [Glioblastoma](https://sec-api.dev/pdufa/glioblastoma): mtap-deleted solid tumors, focused
- [Vopimetostat](https://sec-api.dev/pdufa/vopimetostat): mtap-wild type pancreatic cancer, mtap-deleted and ras-mutant metastatic pancreatic ductal adenocarcinoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tngx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TNGX catalysts: Tango Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tngx/catalysts

```bibtex
@misc{secapidev_companies_tngx_catalysts_20261116,
  title        = {TNGX catalysts: Tango Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tngx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tngx_catalysts_20261116","title":"TNGX catalysts: Tango Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tngx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
